{"id":"abp-745-dose-a","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-15%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL3700786","moleculeType":"Small molecule","molecularWeight":"399.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to both PD-1 and CTLA-4, ABP-745 enhances T-cell activation and proliferation, leading to an anti-tumor immune response. This mechanism is thought to be beneficial in treating various types of cancer.","oneSentence":"ABP-745 is a bispecific antibody that targets and blocks PD-1 and CTLA-4 receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:24.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma, metastatic"}]},"trialDetails":[{"nctId":"NCT07303777","phase":"PHASE2","title":"Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2026-04","conditions":"Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management","enrollment":200},{"nctId":"NCT07145229","phase":"PHASE2","title":"Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare","status":"RECRUITING","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2025-08-26","conditions":"Acute Gouty Arthritis, Gout Flare, Gout Flares","enrollment":380},{"nctId":"NCT06258213","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2024-01-23","conditions":"Gout, Acute Gout Flare, Gout Flares","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1897,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABP-745 Dose A","genericName":"ABP-745 Dose A","companyName":"Atom Therapeutics Co., Ltd","companyId":"atom-therapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP-745 Dose A is being studied in a Phase II clinical trial for its efficacy and safety in treating conditions such as atherosclerosis, cardiovascular disease, and acute gouty arthritis. The study is comparing ABP-745 Dose A to a placebo and ABP-745 Dose B in patients with atherosclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}